Form 4: AIM ImmunoTech CEO Thomas Equels Increases Stake with $5,060 Stock Purchase
SEC Form 4 Filing
AIM ImmunoTech CEO Thomas Equels acquired 44,000 shares of common stock at $0.115 per share, increasing his direct holdings to 1,808,029 shares.
Summary
- On March 4, 2025, Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., purchased 44,000 shares of the company's common stock.
- The purchase price was $0.115 per share, totaling $5,060.
- Following the transaction, Equels directly owns 1,808,029 shares of AIM ImmunoTech Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's stock purchase is a positive signal, but the document is primarily a regulatory filing.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of stock purchase transaction |
| 03/05/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.